Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -135.91% | 126.19% | -403.27% | -322.84% | -222.54% |
| Total Depreciation and Amortization | 8.83% | 15.86% | 18.02% | 28.68% | 3.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.75% | -11.94% | 62.02% | 58.84% | 47.62% |
| Change in Net Operating Assets | 76.89% | 66.14% | 110.89% | 47.91% | 15.61% |
| Cash from Operations | 136.91% | 132.03% | 0.15% | 30.60% | 24.15% |
| Capital Expenditure | 80.66% | 59.23% | 25.54% | -15.73% | -36.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -75.34% | -27.15% | -80.77% | 1,842.34% | 1,288.87% |
| Cash from Investing | -73.20% | -7.80% | -90.78% | 1,111.52% | 343.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16,205.81% | -12,388.65% | -239,000.00% | -- | -- |
| Issuance of Common Stock | -37.19% | -68.16% | -51.33% | -45.85% | -56.37% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -142.88% | -142.88% | -142.88% | -- | -- |
| Cash from Financing | -404.96% | -256.83% | -234.88% | -203.07% | -35.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.61% | 218.62% | -145.09% | 218.73% | 126.92% |